MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

STERIS PLC

Gesloten

SectorGezondheidszorg

221.06 -2.98

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

220.47

Max

226.95

Belangrijke statistieken

By Trading Economics

Inkomsten

16M

173M

Verkoop

42M

1.4B

K/W

Sectorgemiddelde

36.498

63.778

EPS

2.32

Dividendrendement

1.01

Winstmarge

12.643

Werknemers

18,000

EBITDA

-85M

245M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+16.45% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.01%

2.39%

Volgende Winsten

7 mei 2025

Volgende dividenddatum

25 jun 2025

Volgende Ex Dividend datum

11 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

22B

Vorige openingsprijs

224.04

Vorige sluitingsprijs

221.06

Nieuwssentiment

By Acuity

26%

74%

73 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

STERIS PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2025, 21:35 UTC

Winsten

Steris: Outlook Does Not Reflect Any Potential Impact From New Tariffs >STE

5 feb 2025, 21:34 UTC

Winsten

Steris: FY25 Guidance Change Is Primarily Due to Currency >STE

5 feb 2025, 21:34 UTC

Winsten

Steris Cuts FY25 Revenue View to Increase of About 6% From Prior View for 6.5%-7%>STE

5 feb 2025, 21:33 UTC

Winsten

Steris 3Q EPS $1.75 >STE

5 feb 2025, 21:30 UTC

Winsten

Steris Sees FY Adj EPS $9.05-Adj EPS $9.15 >STE

5 feb 2025, 21:30 UTC

Winsten

Steris 3Q Rev $1.4B >STE

5 feb 2025, 21:30 UTC

Winsten

Steris 3Q Adj EPS $2.32 >STE

6 nov 2024, 21:41 UTC

Winsten

Steris Backs FY25 Revenue Up 6.5%-7.5% >STE

6 nov 2024, 21:40 UTC

Winsten

Steris 2Q EPS $1.51 >STE

6 nov 2024, 21:30 UTC

Winsten

Steris Sees FY Adj EPS $9.05-Adj EPS $9.25 >STE

6 nov 2024, 21:30 UTC

Winsten

Steris 2Q Adj EPS $2.14 >STE

6 nov 2024, 21:30 UTC

Winsten

Steris 2Q Rev $1.3B >STE

6 aug 2024, 20:36 UTC

Winsten

Steris 1Q Adj EPS $2.03 >STE

6 aug 2024, 20:30 UTC

Winsten

Steris 1Q Net $139.9M >STE

6 aug 2024, 20:30 UTC

Winsten

Steris 1Q EPS $1.41 >STE

6 aug 2024, 20:30 UTC

Winsten

Steris Sees FY Adj EPS $9.05-Adj EPS $9.25 >STE

3 jun 2024, 11:03 UTC

Acquisities, Fusies, Overnames

PEAK ROCK Cap Affil COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION of HUFRIEDYGROUP

31 mei 2024, 20:47 UTC

Acquisities, Fusies, Overnames

Steris Completes $787.5M Sale of Dental Segment to Peak Rock Capital

8 mei 2024, 20:40 UTC

Winsten

Steris Sees FY25 Adj EPS $9.05-Adj EPS $9.25 >STE

8 mei 2024, 20:39 UTC

Winsten

Steris: Plan Includes Restructuring of the Healthcare Surgical Business in Europe >STE

8 mei 2024, 20:39 UTC

Winsten

Steris Announcing a Targeted Restructuring Plan >STE

8 mei 2024, 20:39 UTC

Winsten

Steris 4Q EPS $3.81 >STE

8 mei 2024, 20:30 UTC

Winsten

Steris 4Q Adj EPS $2.58 >STE

11 apr 2024, 11:01 UTC

Acquisities, Fusies, Overnames

Steris Expects Resulting Benefit of Reduction in Interest Expense to Be About $0.35 Per Shr >STE

11 apr 2024, 11:00 UTC

Acquisities, Fusies, Overnames

Steris: Transaction Is Anticipated to Close in 1Q of Fiscal Yr 2025 >STE

11 apr 2024, 10:59 UTC

Acquisities, Fusies, Overnames

Steris: Transaction Terms Include Opportunity to Receive Additional Earnout of Up to $12.5M >STE

11 apr 2024, 10:59 UTC

Acquisities, Fusies, Overnames

Steris: Transaction Is Structured as Equity Sale >STE

11 apr 2024, 10:58 UTC

Acquisities, Fusies, Overnames

Steris Enters Agreement to Divest Dental Segment to Peak Rock Cap for $787.5M >STE

11 apr 2024, 10:58 UTC

Acquisities, Fusies, Overnames

STERIS to Sell Dental Segment to an Affiliate of Peak Rock Capital for $787.5M

Peer Vergelijking

Prijswijziging

STERIS PLC Prognose

Koersdoel

By TipRanks

16.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 265 USD  16.45%

Hoogste 265 USD

Laagste 265 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor STERIS PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technische score

By Trading Central

222.25 / 228.22Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

73 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over STERIS PLC

STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.